Royalty Pharma plc (RPRX) FY2025 Q1 Statement of Cash Flows

Income StatementCash FlowBalance Sheet

Statement of Cash Flows

2025-01-01 to 2025-03-31

Swipe to see the full flow
Royalty Pharma plc cash flow reconciliation, Jan 1, 2025 through Mar 31, 2025One connected Sankey reconciles operating, investing and financing net cash flows through a shared cash pool, from beginning cash to ending cash. Ribbons flow left to right on one dollar scale. Activity totals are dark gray; beginning and ending cash are blue. Cash basis for beginning and ending balances and net cash change: Cash, cash equivalents, and restricted cash. Intermediate calculation bars are lighter gray. Identified asset purchases, sales and maturities are blue in either cash direction. Purple identifies capital transactions such as borrowing, repayments, share issuance and dividends. Read chart description and values below for full signed amounts, including zero items.Cash collections from financial royalty assets → operating reconciliation: $829,737,000.00Other royalty cash collections → operating reconciliation: $31,759,000.00Distributions from equity method investees → operating reconciliation: $13,396,000.00Interest received → operating reconciliation: $12,025,000.00Cash collections from intangible royalty assets → operating reconciliation: $177,000.00operating reconciliation → Net cash from operating activities: $596,076,000.00operating reconciliation → Interest paid: $138,822,000.00operating reconciliation → Payments for operating and professional costs: $101,696,000.00operating reconciliation → Development-stage funding payments: $50,500,000.00Proceeds from sales of available for sale debt securities → investing reconciliation: $510,553,000.00Distributions from equity method investees → investing reconciliation: $36,262,000.00Proceeds from available for sale debt securities → investing reconciliation: $12,586,000.00investing reconciliation → Net cash from investing activities: $503,917,000.00investing reconciliation → Milestone payments: $50,000,000.00investing reconciliation → Purchases of equity securities: $4,427,000.00investing reconciliation → Acquisitions of financial royalty assets: $1,057,000.00Net cash used in financing activities → financing reconciliation: $941,299,000.00Contributions from non-controlling interests - other → financing reconciliation: $1,077,000.00Contributions from legacy non-controlling interests - R&D → financing reconciliation: $220,000.00financing reconciliation → Repurchases of Class A ordinary shares: $708,781,000.00financing reconciliation → Dividends to shareholders: $95,357,000.00financing reconciliation → Distributions to legacy non-controlling interests - Portfolio Receipts: $84,625,000.00financing reconciliation → Distributions to continuing non-controlling interests: $53,833,000.00Beginning cash: Cash, cash equivalents, and restricted cash → Cash sources and uses: $929,026,000.00Net cash from operating activities → Cash sources and uses: $596,076,000.00Net cash from investing activities → Cash sources and uses: $503,917,000.00Cash sources and uses → Ending cash: Cash, cash equivalents, and restricted cash: $1,087,720,000.00Cash sources and uses → Net cash used in financing activities: $941,299,000.00Cash collections from intangible royalty assets: $177,000.00Intangible royalty collections+$177.00 KCash collections from financial royalty assets: $829,737,000.00Financial royalty collections+$829.74 MInterest paid: -$138,822,000.00Interest paid−$138.82 MInterest received: $12,025,000.00Interest received+$12.03 MPayments for operating and professional costs: -$101,696,000.00Operating & professional costs−$101.70 MDistributions from equity method investees: $13,396,000.00Equity-method distributions+$13.40 MDevelopment-stage funding payments: -$50,500,000.00Development-stage funding payments−$50.50 MOther royalty cash collections: $31,759,000.00Other royalty cash collections+$31.76 MNet cash from operating activities: $596,076,000.00Operating cash+$596.08 Moperating reconciliation: $887,094,000.00Distributions to continuing non-controlling interests: -$53,833,000.00Paid to noncontrolling interests−$53.83 MRepurchases of Class A ordinary shares: -$708,781,000.00Common stock repurchases−$708.78 MContributions from legacy non-controlling interests - R&D: $220,000.00From legacy noncontrolling, R&D+$220.00 KDistributions to legacy non-controlling interests - Portfolio Receipts: -$84,625,000.00Legacy noncontrolling, portfolio−$84.63 MContributions from non-controlling interests - other: $1,077,000.00From noncontrolling, other+$1.08 MDividends to shareholders: -$95,357,000.00Dividends to shareholders−$95.36 MNet cash used in financing activities: -$941,299,000.00. Cash required to fund net payments.Financing cash−$941.30 Mfinancing reconciliation: $942,596,000.00Proceeds from available for sale debt securities: $12,586,000.00AFS securities sales+$12.59 MDistributions from equity method investees: $36,262,000.00Equity-method return of capital+$36.26 MMilestone payments: -$50,000,000.00Milestone payments−$50.00 MInvestments in equity method investees: $0.00Proceeds from sales of available for sale debt securities: $510,553,000.00AFS debt securities sales+$510.55 MAcquisitions of financial royalty assets: -$1,057,000.00Finance receivable purchases−$1.06 MPurchases of equity securities: -$4,427,000.00Purchases of equity securities−$4.43 MNet cash from investing activities: $503,917,000.00Investing cash+$503.92 Minvesting reconciliation: $559,401,000.00Cash sources and uses: $2,029,019,000.00Beginning cash: Cash, cash equivalents, and restricted cash: $929,026,000.00Beginning cash$929.03 MEnding cash: Cash, cash equivalents, and restricted cash: $1,087,720,000.00Ending cash$1.09 BCASH RECONCILIATIONOperatingflowsInvestingflowsFinancingflowsFree cash flowNot availableCash flow / Net incomeUnavailableOperating cash flow ÷ net incomeNet cash change+$158.69 MEnding cash − beginning cash
Chart details

Royalty Pharma plc cash flow reconciliation, Jan 1, 2025 through Mar 31, 2025

Cash flows for Jan 1, 2025 through Mar 31, 2025. Cash basis: Cash, cash equivalents, and restricted cash. Beginning cash: Dec 31, 2024. Ending cash: Mar 31, 2025. Beginning and ending cash are dated balances. Positive cash flows add cash; negative cash flows reduce it.

Beginning cash on Dec 31, 2024
929,026,000 US dollars. Beginning cash: Cash, cash equivalents, and restricted cash
Operating activities
596,076,000 US dollars. Net cash provided.
Cash collections from intangible royalty assets
177,000 US dollars
Cash collections from financial royalty assets
829,737,000 US dollars
Interest paid
negative 138,822,000 US dollars
Interest received
12,025,000 US dollars
Payments for operating and professional costs
negative 101,696,000 US dollars
Distributions from equity method investees
13,396,000 US dollars
Development-stage funding payments
negative 50,500,000 US dollars
Other royalty cash collections
31,759,000 US dollars
Investing activities
503,917,000 US dollars. Net cash provided.
Proceeds from available for sale debt securities
12,586,000 US dollars
Distributions from equity method investees
36,262,000 US dollars
Milestone payments
negative 50,000,000 US dollars
Investments in equity method investees
0 US dollars
Proceeds from sales of available for sale debt securities
510,553,000 US dollars
Acquisitions of financial royalty assets
negative 1,057,000 US dollars
Purchases of equity securities
negative 4,427,000 US dollars
Financing activities
negative 941,299,000 US dollars. Net cash used.
Distributions to continuing non-controlling interests
negative 53,833,000 US dollars
Repurchases of Class A ordinary shares
negative 708,781,000 US dollars
Contributions from legacy non-controlling interests - R&D
220,000 US dollars
Distributions to legacy non-controlling interests - Portfolio Receipts
negative 84,625,000 US dollars
Contributions from non-controlling interests - other
1,077,000 US dollars
Dividends to shareholders
negative 95,357,000 US dollars
Operating adjustment reconciliation
887,094,000 US dollars. Intermediate calculation joining the operating reconciliation branches. Its gross amount includes any portion of net income routed through this junction. It is not an additional cash source or use.
financing gross reconciliation
942,596,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
investing gross reconciliation
559,401,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
Exchange-rate effect
0 US dollars
Ending cash on Mar 31, 2025
1,087,720,000 US dollars. Ending cash: Cash, cash equivalents, and restricted cash
Cash sources and uses
2,029,019,000 US dollars. Opening cash plus net sources, equal to net uses plus ending cash.
Net cash change
158,694,000 US dollars. Ending cash minus beginning cash.
Cash flow / Net income
Unavailable. Operating cash flow and reconciliation net income for the same period are required.

Chart connections

  • Beginning cash plus operating, investing and financing cash flows plus the exchange-rate effect equals ending cash. Negative amounts reduce cash.
  • Financing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Investing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Operating reconciliation adjustments are not all independent cash receipts.
  • Each activity has one net cash bar connected to the shared cash pool. Positive activity totals enter the pool; negative activity totals leave the pool to fund that activity's net payments. The central pool does not assign a particular funding source to a particular payment.
  • The intermediate calculation bars include both sides of the displayed activity breakdowns; they are not additional cash flows.
Royalty Pharma plc (RPRX) FY2025 Q1 Statement of Cash Flows Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!